biostudies-literatureImran TFNIGMSe0295359https://www.ebi.ac.uk/biostudies/studies/S-EPMC10699593biostudies-literatureUnknown18(12)<h4>Background</h4>Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear.<h4>Objective</h4>The purpose of this study is to examine the effects of PCSK9 inhibitPloS oneProprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.PMC10699593Project number: 5P20GM103652-10, Sub-Project ID: 9499Jacobson ABogin SKim SWu WCKhan AAAspry KImran TFKhalid MKhan AChoudhary GHas PErqou SfalseProprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.<h4>Background</h4>Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear.<h4>Objective</h4>The purpose of this study is to examine the effects of PCSK9 inhibit2023-01-01T00:00:00Z20232025-04-05T13:02:34.018Z2024-11-06T04:59:28.894ZS-EPMC106995933805568610.1371/journal.pone.0295359